NEW YORK, Dec. 13 — Athersys has struck a deal with Pfizer to provide human cell lines that express protein drug targets, the company said Thursday. By the terms of the deal, Athersys will receive licensing fees for each validated line it delivers, milestone payments on candidate therapeutics, and royalties on any products developed.

The Pfizer deal is the fourth collaboration that Athersys has arranged for its RAGE platform, a gene expression system that produces proteins from human genes without cloning or cDNA libraries.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.